Use of lactalapoprotein in prevention and treatment of microbial or virus infection

A technology of prosthetic protein and milk, which is applied in the direction of antiviral agents, anti-infective drugs, hydrolyzed protein components, etc., to achieve the effect of preventing dental caries and inhibiting adhesion

Inactive Publication Date: 2005-02-09
WESTGATE BIOLOGICAL
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0015] Therefore, there is an urgent need for new antimicrobial substances for the treatment of this antibiotic-resistant infection and some other infections that cannot be treated by conventional therapies, as well as new antiviral substances for the treatment of viruses for which few effective treatments currently exist Infect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of lactalapoprotein in prevention and treatment of microbial or virus infection
  • Use of lactalapoprotein in prevention and treatment of microbial or virus infection
  • Use of lactalapoprotein in prevention and treatment of microbial or virus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0130] Embodiment 1: Preparation of whey free fatty acid and whey apoprotein

[0131]Lactose-free whey powder (Carbelac 80 from Carbery Dairy) was used as starting material. Carbelac80 is a typical 100% whey, and the typical Carbelac80 contains 0% skim milk, 80% protein, 5% moisture, 8% fat and 3% dust. 30 g of this starting material were dissolved in phosphate buffered saline (PBS) pH 6.8 in a final volume of 1 liter. To this was added 1 g of a suitable composition of various esterases (mainly lipases, but also amylases and proteases), eg "crude extract of type II esterase from porcine pancreas" available from Sigma. The mixture was incubated at 37°C for 18 hours; heat-treated at 60°C for 10 minutes to inactivate the enzyme; and spray dried.

[0132] Other suitable esterases include, but are not limited to, the commercial products "Palatase" and "Novozyme" from Novo Nordisk (Copenhagen, Denmark), when the two enzymes are mixed 50:50 (w / w) and 1 g is added per 30 g In lacto...

Embodiment 2

[0167] The growth inhibitory properties of standard formulations against fresh clinical isolates of C. albicans were evaluated using the growth assay described above in the Methods and Materials. The analysis was performed in a microtiter format, with quadruplicate assays for each concentration tested. Yeast growth was monitored over 20 hours at 600 nm and the results are shown in FIG. 6 . The standard formulation (5 mg / ml) showed almost 90% growth inhibition relative to the control to which 0 mg / ml standard formulation was added. The results for the standard formulation at 1 mg / ml were in between.

[0168] A similar analysis process is adopted, except that the substance to be tested is added after 5 hours of normal yeast growth, which is called interference analysis herein. The concentration range of standard preparations added is 0-8mg / ml. The detection concentration was set in this way to ensure that when the preheated (to 37°C) solution to be tested was added, the dilut...

Embodiment 3

[0170] Standard formulations inhibited adhesion in addition to inhibiting growth. Adhesion assay methods are described above in Methods and Materials. Using the same formulation as in Example 2, its inhibitory effect on the adhesion of the same fresh clinical isolate of Candida albicans to oral epithelial cells is shown in Figure 8 and Figure 9 .

[0171] In Figure 8, yeast cells have been exposed to the standard formulation for 10 minutes prior to the addition of oral epithelial cells. In Figure 9, oral epithelial cells have been exposed to the standard formulation for 10 minutes before adding the yeast suspension.

[0172] The "control" in both assays represents the adhesion achieved under the test conditions in the absence of inhibitory substances; 41% and 35%, respectively. Addition of 1 mg / ml standard formulation to Candida pretreatment reduced adhesion to 20% (53% inhibition), while addition of the same concentration of standard formulation to oral epithelial cell pret...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
Login to view more

Abstract

The present invention relates to use of a milk apoprotein or a mixture thereof to prevent or treat microbial or viral infection of the human or animal body. It is believed that this is achieved by inhibiting adhesion of potential pathogens. More preferably, at least one milk apoprotein or a mixture thereof is administered, simultaneously or sequentially, with either or both of at least one free fatty acid or a mixture thereof or a monoglyceride thereof; and / or at least one organic acid or a salt or ester thereof or a mixture thereof. The active agent(s) may be delivered by means of a pharmaceutically acceptable delivery system which includes parenteral solutions, ointments, eye drops, nasal sprays, intravaginal devices, surgical dressings, medical foods or drinks, oral healthcare formulations and medicaments for mucosal applications.

Description

[0001] The present invention relates to the use of milk apoprotein in preventing or treating the infection of human body or animal body by microorganism or virus. More specifically, these milk apoproteins can be used alone or in combination with one or more short-chain organic acids (such as citric acid) and their salts or esters, and / or one or more free fatty acids and their used in combination with monoesters to inhibit the adhesion and / or growth of potential pathogens. Background of the invention [0002] Milk is a whitish fluid produced by the mammary glands of mature female mammals after giving birth. Mammals are warm-blooded vertebrates belonging to the class Mammalia, including humans. More preferred mammals for the purposes of the present invention are ungulate artiodactyls belonging to the suborder Ruminants, such as cattle, sheep, goats, deer and giraffes. In the present invention, milk from cows and goats is the preferred source of milk apoprotein simply because m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/06A23L29/00A61K6/60A61K8/00A61K8/64A61K8/72A61K8/96A61K9/12A61K35/20A61K38/00A61K38/01A61K38/17A61K47/12A61K47/14A61K47/22A61P1/00A61P1/02A61P11/02A61P15/00A61P17/00A61P27/02A61P31/00A61P31/10A61Q11/00
CPCA61K38/1709A61K35/20A61K38/018A61P1/00A61P1/02A61P11/02A61P15/00A61P17/00A61P27/02A61P31/00A61P31/02A61P31/04A61P31/10A61P31/12A61K38/17
Inventor M·A·福兰D·布拉迪
Owner WESTGATE BIOLOGICAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap